# US 2016/0250202 A1 · Mast Cell Stabilizers to Prevent or Treat Laminitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250202 A1
- Document ID: US20160250202A1
- Status: Published application
- Kind: A1
- Application number: 15/150,061
- Filed: 2016-05-09
- Published: 2016-09-01
- Earliest claimed: 2004-08-02
- Assignees: Wilowcroft Pharm Inc.
- Applicants: Wilowcroft Pharm Inc.
- Inventors: Charles F. Owen
- Web page: https://patentgrep.com/patent/US20160250202A1

## CPC

- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis.

## Claims

### Claim 1

A method for the treatment of laminitis, the method comprising administering a mast cell stabilizer to a subject in need thereof, wherein the mast cell stabilizer treats laminitis in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is selected from the group consisting of horse, pig, cow, sheep, goat, mule, donkey, buffalo, and camel.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mast cell stabilizer is administered one time, two times, daily, every other day, every three days, every four days, every five days, every six days, twice weekly, weekly, every other week, twice a month, monthly, or every other month.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject suffers from recurring chronic laminitis and wherein the mast cell stabilizer is administered on a daily basis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mast cell stabilizer is selected from the group consisting of nedocromil sodium, cromolyn sodium, pemirolast, lodoxamise trometamol, and odoxamide.

### Claim 6 (depends on 5)

The method of claim 5, wherein the mast cell stabilizer is nedocromil sodium.

### Claim 7 (depends on 6)

The method of claim 6, wherein the nedocromil sodium is administered through intravenous injection.

### Claim 8 (depends on 1)

The method of claim 1, the method further comprising administering to the subject a medicament selected from the group consisting of anti-inflammatory, antihistamine, and analgesic.

### Claim 9 (depends on 1)

The method of claim 1, the method further comprising administering to the subject stem cells.

### Claim 10 (depends on 1)

The method of claim 1, the method further comprising administering the mast cell stabilizer as a second dose within about 18 to about 30 hours after administering a first dose.

### Claim 11 (depends on 1)

The method of claim 1, wherein the mast cell stabilizer is administered in a dose of at least about 3 mg/kg to at least about 10 mg/kg subject body weight.

### Claim 12

A method for the treatment of laminitis, the method comprising inhibiting mast cell degranulation in a subject in need thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the inhibiting mast cell degranulation comprises administrating to the subject a mast cell stabilizer selected from the group consisting of nedocromil sodium, cromolyn sodium, pemirolast, lodoxamise trometamol, and odoxamide.

### Claim 14

A method of preventing laminitis, the method comprising:
a) identifying a subject at risk for laminitis; and
b) administering a mast cell stabilizer to the subject in an amount effective for preventing laminitis.

### Claim 15 (depends on 14)

The method of claim 14, wherein the mast cell stabilizer is administered daily.

### Claim 16 (depends on 14)

The method of claim 14, wherein the mast cell stabilizer is administered daily until the risk of laminitis is diminished.

### Claim 17 (depends on 14)

The method of claim 14, the method further comprising administering to the subject a medicament selected from the group consisting of anti-inflammatory, analgesic, and antihistamine.

### Claim 18 (depends on 17)

The method of claim 17, wherein the medicament is antihistamine and the antihistamine is selected from the group consisting of benadryl, histadyl, triplennamine, pyrilaminic maleate, and chlortrimeton maleate.

### Claim at position 19

-21. (canceled)
